| Name | Title | Contact Details |
|---|
Since its beginning in 1902` Cedars-Sinai has evolved to meet the healthcare needs of one of the most diverse regions in the nation` continually setting new standards for quality and innovation in patient care` research` teaching and community service. Today` Cedars-Sinai is widely known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai receives consistent recognition for our excellence. Our awards include; being named one of America`s Best Hospitals by U.S. News & World Report` receiving the National Research Corporation`s Consumer Choice Award 19 years in a row for providing the highest-quality medical care in Los Angeles` achieving the longest-running Magnet designation for nursing excellence in California` and being recognized as The Advisory Board Company`s 2017 Workplace of the Year` an award Cedars-Sinai has won three years in a row. This annual award recognizes hospitals and health systems nationwide that have outstanding levels of employee engagement. Cedars-Sinai is a leader in the clinical care and research of heart disease` cancer and brain disorders` among other areas. Pioneering research achievements include using cardiac stem cells to repair damaged hearts` developing minimally invasive surgical techniques and discovering new types of drugs to target cancer more precisely. Cedars-Sinai also impacts the future of healthcare through education programs that encompass everything from highly competitive medical residency and fellowship programs to a biomedical science and translational medicine PhD program` advanced training for nurses and educational opportunities for allied health professionals. Most notably` Cedars-Sinai demonstrates a longstanding commitment to strengthening the Los Angeles community through wide-ranging programs that improve the health of its most vulnerable residents.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
Fisher Center for Alzheimers Research Foundation is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lodi Memorial Hospital is a general medical and surgical hospital in Lodi, CA, with 214 beds. Survey data for the latest year available shows that 31,080 patients visited the hospital's emergency room. The hospital had a total of 7,139 admissions. Its physicians performed 2,124 inpatient and 2,140 outpatient surgeries.
Evans Analytical Group (EAG) has been a global leader in surface analysis and materials characterization for over 29 years, delivering innovative analytical services and solutions with uncompromising scientific integrity.